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Arising from the ablation of the cytoskeletal protein dystrophin, Duchenne Muscular Dystrophy (DMD) 
is a debilitating and fatal skeletal muscle wasting disease underpinned by metabolic insufficiency. 
The inability to facilitate adequate energy production may impede calcium (Ca2+) buffering within, 
and the regenerative capacity of, dystrophic muscle. Therefore, increasing the metabogenic potential 
could represent an effective treatment avenue. The aim of our study was to determine the efficacy of 
adenylosuccinic acid (ASA), a purine nucleotide cycle metabolite, to stimulate metabolism and buffer 
skeletal muscle damage in the mdx mouse model of DMD. Dystrophin-positive control (C57BL/10) and 
dystrophin-deficient mdx mice were treated with ASA (3000 µg.mL−1) in drinking water. Following 
the 8-week treatment period, metabolism, mitochondrial density, viability and superoxide (O2−) 
production, as well as skeletal muscle histopathology, were assessed. ASA treatment significantly 
improved the histopathological features of murine DMD by reducing damage area, the number of 
centronucleated fibres, lipid accumulation, connective tissue infiltration and Ca2+ content of mdx tibialis 
anterior. These effects were independent of upregulated utrophin expression in the tibialis anterior. ASA 
treatment also increased mitochondrial viability in mdx flexor digitorum brevis fibres and concomitantly 
reduced o2− production, an effect that was also observed in cultured immortalised human DMD 
myoblasts. Our data indicates that ASA has a protective effect on mdx skeletal muscles.
Characterised by progressive and fatal muscular weakness and degeneration, Duchenne Muscular Dystrophy 
(DMD) is a rare neuromuscular disorder that arises from the loss of dystrophin at the sarcolemma due to a 
genetic defect in the encoding gene1. It is generally accepted that the pathophysiology of DMD is induced by 
calcium (Ca2+) dysregulation secondary to dystrophin deficiency2–7 which leads to activation of Ca2+-dependent 
enzymes8–11 and the progression of muscle damage, degeneration and wasting, and chronic inflammation12. As 
muscle is replaced with fatty and/or fibrous connective tissue, weakness ensues. Consequently, DMD sufferers 
are typically wheelchair bound by early adolescence13 and die from cardiorespiratory failure before thirty years 
of age13. One often unaddressed characteristic of dystrophin-deficient muscle is associated metabolic dysfunc-
tion, which is evident across various metabolic pathways responsible for cellular energy production (as reviewed 
in14). While this metabolic dysfunction is often regarded as a secondary consequence of Ca2+-dependent disease 
sequelae, we hypothesised that mitochondrial dysfunction in particular is a core aetiological perturbation14 that 
could be therapeutically exploited. Together with: (1) the initial observations of slower running speeds in mdx 
mice15; (2) the observations that metabolic dysfunction is present in dystrophic myoblasts prior to the normal 
expression of dystrophin protein16; (3) the observation that mitochondrial adenosine triphosphate (ATP) produc-
tion rate is reduced in isolated dystrophic mitochondria removed from the dystrophic pathological environment 
and bathed in the presence of an optimal extracellular environment17; and (4) positive clinical trials data with the 
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mitochondrial short chain CoQ10 analogue, idebenone, in DMD patients18; our hypothesis of metabolic dysfunc-
tion as an aetiological driver of DMD has been given credence.
During the extensive investigation of metabolic therapies to treat DMD in the 1980–90’s (as reviewed by 
us previously19), one promising therapeutic was the purine nucleotide, adenylosuccinic acid (ASA), which 
was investigated in a long term, Phase I clinical trial including both Duchenne and Becker (a milder var-
iation) MD patients20. ASA is a metabolite of the Purine Nucleotide Cycle (PNC), which is activated during 
metabolic stress to drive the recovery of ATP from inosine monophosphate (IMP) via the reversible reaction: 
IMP → AMP → ADP → ATP20. The PNC also produces fumarate that can be shuttled into the mitochondria 
to anaplerotically expand the Tricarboxylic (citric) Acid (TCA) cycle and, therefore, enhance ATP production 
capacity20. Following ASA administration, patients anecdotally reported instantaneous increases in energy, stam-
ina and endurance20. Functionally, ASA therapy maintained the ability to stand erect, rise from the floor and walk 
without falling, which was accompanied with decreased serum creatine kinase (CK) levels and improvements 
in histopathological hallmarks indicating a reduction in muscle damage20. The subsequent replacement of func-
tional muscle with fatty and connective tissue is a feature of disease progression and leads to reduced physical 
capacity21–23. In support of ASA-induced protection, significantly reduced fatty tissue infiltration was observed in 
muscle biopsies taken at multiple time points during the four-year trial. The ability of ASA to improve key features 
of DMD, including the maintenance of muscle function, may arise from its capacity to promote ATP production 
by increased purine salvage and aerobic metabolism via purine nucleotide cycling and anaplerotic expansion of 
the TCA cycle, respectively. Recently, it has been demonstrated that ASA stimulates exocytosis of insulin from 
pancreatic β cells, and that inhibition of ASA’s regulatory enzymes within the PNC impairs glucose-stimulated 
insulin secretion24. This suggests that ASA activates energy producing pathways, which could be beneficial to 
overcome the chronic metabolic impairment of dystrophin-deficient muscles17,25–31.
A major limitation of the clinical ASA trial is that only one DMD patient completed the study long-term. ASA 
was beneficial in two BMD patients, but its long-term capacity to affect the progression of DMD has never been 
determined. Thus, this proof-of-concept study aimed to determine the therapeutic potential of ASA for the treat-
ment of DMD. We investigated the effects of 8 weeks of ASA therapy in healthy (control; CON) and dystrophic 
(mdx) mice, and specifically assessed whether ASA supplementation could attenuate the histopathological pro-
gression of DMD by improving bioenergetical status and mitochondrial capacity of skeletal muscle. We hypoth-
esised that ASA therapy would: (1) reduce the histopathological hallmarks of DMD such as muscle damage and 
lipid and connective tissue infiltration; and (2) improve mitochondrial function and the overall bioenergetical 
capacity of skeletal muscles in mdx mice.
Materials and Methods
ethical approval. All experimental procedures were approved by the Victoria University Animal Ethics 
Committee and conformed to the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes.
Animals and treatment. Three-week old male C57Bl/10ScSn (normal wild-type strain; CON) and 
C57Bl/10mdx (mdx) mice were purchased from Animal Resources Centre (Western Australia, Australia) and 
housed at the Western Centre for Health, Research and Education (Sunshine Hospital, Victoria, Australia) on 
a 12:12 hour light-dark cycle with ad libitum access to food and water. Mice of the same strain were randomly 
assigned to housing cages of four by animal technicians on arrival. At four weeks of age, cages were randomly 
block assigned into untreated (CON and mdx) and treated (CON ASA and mdx ASA) groups. For the ASA 
treated groups, we aimed to administer a human equivalent dose of 25 mg/kg/day as this is the only specified 
dose that was delivered via a non-intravenous route during the clinical trial of ASA20. After taking into account 
blood volume and the average daily water intake of a mouse, mice were administered 3000 µg/mL ASA in RO 
drinking water (pH 7.2). A progressive treatment protocol was employed to enable the detection of any toxic or 
adverse effects in mice. Mice were initially administered 3 µg/mL ASA for 3 days and this was increased to 30 µg/
mL for the next 4 days, and 300 µg/mL of ASA for one week. Since no adverse effects were observed, 3000 µg/
mL ASA was delivered for the remaining 6 weeks of the treatment period. Based upon cage water consump-
tion, the average daily exposure of mice during the first 7 days was 2.99 ± 0.10 mg/kg/day for CON mice and 
3.04 ± 0.19 mg/kg/day for mdx mice. In the second week, the daily exposure of mice was 35.89 ± 2.48 mg/kg/day 
for CON mice and 40.20 ± 2.20 mg/kg/day for mdx mice. The daily exposure for the final 6 weeks of treatment 
was 325.74 ± 11.43 mg/kg/day for CON mice and 335.64 ± 50.42 mg/kg/day for mdx mice. Using a conversion 
coefficient recommended by the US Food and Drug Administration of 12.3 to account for differences in body 
surface area between humans and mice32, the estimated daily human equivalent dosage was ~26 mg/kg/day for 
CON ASA mice and ~27 mg/kg/day for mdx ASA mice. This approximates the human equivalent target dosage of 
25 mg/kg/day in the ASA clinical trials20.
At the conclusion of the treatment period, mice were deeply anaesthetised (intraperitoneal injection of 60 mg/
kg sodium pentobarbitone) and non-survival surgery was performed. Skeletal muscles were removed for analyses 
in the following order: (1) left and right flexor digitorum brevis (FDB) for the measurement of mitochondrial 
parameters; (2) left and right extensor digitorum brevis (EDL) and soleus for the assessment of contractile prop-
erties; (3) right and left tibialis anterior (TA) for the analysis of histopathology and metabolites, respectively; and 
(4) right and left quadriceps for western blot analyses of proteins of interest. The remaining hind limb skeletal 
muscles, diaphragm and organs (including the heart, lungs, liver and spleen) were also surgically excised and 
weighed.
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Histopathology. The right TA was covered in optimal cutting temperature compound (Sakura Finetek) 
and snap frozen in liquid nitrogen-cooled isopentane. TA’s were sectioned on a cryostat (10 µm, -20 °C, Leica 
CM1950) and mounted onto glass slides (Menzel-Glaser).
Five histological stains were employed to assess various features of the dystrophic histopathology. 
Haematoxylin & Eosin (H&E) was utilised to assess fibre size, damage area (measured as areas of myofibres disso-
lution with inflammatory/satellite cell infiltrate33) and centronucleated fibres, while Oil Red O (ORO) evaluated 
lipid accumulation within the whole muscle. Collagen deposition, which increases as the disease progresses, 
was evaluated via Gomori Trichrome staining (HT10316, Sigma Aldrich) with relative Ca2+ content assessed 
via Alizarin Red staining (Merck Millipore). Finally, succinate dehydrogenase (SDH) activity was measured via 
histochemical analysis to determine any differences in oxidative capacity of the TA34. All histological protocols 
were performed as described previously35,36. For H&E and ORO, slides were imaged on a microscope (Zeiss Axio 
Imager Z2) at 20x and 10x magnification, respectively. For Gomori Trichrome, Alizarin Red and SDH stains, 
slides were imaged on a microscope (Olympus, Tokyo, Japan) at 40x magnification. All images were analysed 
using ImageJ software (NIH, USA) as previously described36,37.
contractile properties. Muscle (EDL and soleus) dissection and preparation, and the contraction protocol 
was performed as previously described37. Optimal length (Lo) was determined via a series of twitch contractions, 
and the left EDL and SOL were stimulated to contract tetanically (maximal activation at 100 Hz) to obtain abso-
lute force (Po). Muscles were then blotted dry and weighed and the cross-sectional area (CSA) was determined 
(CSA = muscle mass (g)/(Lo (cm)*[fibre length/muscle length])*density. For EDL and soleus, the fibre length/
muscle length ratio was 0.44 and 0.71, respectively, and the density was 1.06 g/cm2 for both muscles38. Specific 
force (sPo) for each muscle was calculated sPo = (Po/1000)/CSA.
Mitochondrial respiration measurement. Mitochondrial respiratory parameters were quantified in 
isolated muscle fibres as described previously by Schuh et al.39. Left and right FDB were excised from anaes-
thetised mice and incubated in pre-warmed dissociation media (DMEM, Gibco, 10566016; 2% FBS, Bovogen 
Biologicals; 4 mg/mL collagenase A, Roche, 10103586001; 50 µg/mL gentamycin, Sigma Aldrich, G1397) for 
1 hour and 45 minutes (37 °C, 5% CO2). Following the dissociation period, FDB bundles were placed into incu-
bation media (DMEM, Gibco, 10566016; 2% FBS, Bovogen Biologicals; 50 µg/mL gentamycin, Sigma Aldrich 
G1397) and bundles were triturated with graduated pipette tips to yield single fibres. To facilitate fibre adherence 
to Seahorse XF24 cell culture V7 microplates (Seahorse Bioscience, MA, USA), all wells of the microplate were 
coated with extracellular matrix (Sigma Aldrich, E1270) and a 75 µL aliquot of isolated fibres were placed into 
the coated wells (all samples were run in triplicate). Confluency (~60%) was determined using a light micro-
scope. Following overnight incubation, incubation media was replaced with pre-warmed measurement buffer 
(120 mM NaCl, 3.5 mM KCl, 1.3 mM CaCl2, 0.4 mM KH2PO4, 1 mM MgCl2, 5 mM HEPES, 2.5 mM D-glucose and 
0.5mM L-carnitine, pH 7.4) and the microplate was re-incubated for 2 hours for pH and temperature equilibra-
tion. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were determined for various 
respiratory states using a mitochondrial stress test protocol. A loaded Sensor Cartridge (all final concentrations in 
the well following injection: Port A: 2 µg/mL oligomycin; Port B: 400 nM FCCP and 10 mM pyruvate; Port C: 1 µM 
antimycin A) was inserted into the Seahorse Bioscience XF24 Analyser and once calibration was completed, the 
sample loaded microplate was inserted. Following an equilibration period, basal OCR and ECAR were measured 
with a 3 minute mix, 2 minute wait, and 3 minute measure cycle, which was looped 3 times. Port A was injected 
to induce state 4 respiration and following the 3 mix-wait-measure cycles, Port B was injected to induce state 3 
respiration. Following the subsequent 3 mix-wait-measure cycles, Port C was injected to inhibit respiration and 
detect non-mitochondrial respiration.
Mitochondrial density, viability and superoxide (O2−) production. Mitochondrial viability 
in isolated FDB fibres was assessed by the fluorescent MitoTracker dyes Green and Red. MitoTracker Green 
is a non-selective mitochondrial dye that labels all mitochondria irrespective of the mitochondrial membrane 
potential (∆Ψ) while MitoTracker Red is only taken up into mitochondria with a ∆Ψ. Isolated FDB fibres were 
plated onto a matrigel coated 96 well microplate and confluency was determined using a light microscope. The 
microplate was incubated overnight and 10 minutes prior to the addition of the MitoTracker dyes, FCCP and anti-
mycin A (final concentration of 3 µM each) were added to positive control wells to induce mitochondrial death. 
Following this, a cocktail of MitoTracker Green and Red (final concentration of 200 nM and 50 nM, respectively) 
was added to each well and incubated at 37 °C for 30 minutes. Fibres were then washed twice with Fluorobrite 
media and imaged on an inverted microscope (Olympus, Tokyo, Japan) using FITC and TRITC filters. Images 
were analysed using ImageJ software (NIH, USA) and mitochondrial viability was calculated as a ratio of live 
mitochondria (MitoTracker Red) to total mitochondrial pool (MitoTracker Green).
Mitochondrial O2− production was measured as described by us previously36, using the O2− indicator 
MitoSOX Red, which is selective to mitochondria and fluoresces red when oxidised by mitochondrial O2−. 
Isolated FDB fibres were plated into matrigel-coated wells in triplicate and confluency was determined using a 
light microscope. Plates were incubated overnight and 5 minutes prior to the addition of the MitoTracker dyes, 
antimycin A (final concentration of 3 µM) was added to the positive control wells, which inhibits Complex III 
(CIII) and drives reverse electron flow and maximal O2− production at Complex I (CI). Following this, MitoSOX 
(final concentration of 5 µM) in HBSS/Ca2+/Mg2+ buffer (10 mM HEPES, 150 mM NaCl, 5 mM KCl, 1 mM MgCl, 
1.8 mM CaCl2, pH 7.4) was added to wells and plates were re-incubated at 37 °C for 30 minutes. MitoSOX was 
removed and fibres were counterstained with MitoTracker Green. Fibres were then washed twice with Fluorobrite 
media and imaged as above.
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Western blot analysis of metabolic stress (AMPK), mitochondrial biogenesis (PGC-1α/β), 
respiratory chain proteins (CI-V) and utrophin. Western blot analysis of metabolic stress, mitochon-
drial biogenesis, respiratory chain proteins and utrophin was performed as previously described35. Briefly, fro-
zen quadriceps (for AMPK, PGC-1α/β and CI-V) and TA (utrophin) were homogenised in ice-cold WB buffer 
(40 mM Tris, pH 7.5; 1 mM EDTA; 5 mM EGTA; 0.5% Triton X-100; 25 mM β-glycerophosphate; 25 mM NaF; 
1 mM Na3VO4; 10 μg/ml leupeptin; and 1 mM PMSF), and protein concentrations were determined (DC pro-
tein assay kit, Bio-Rad Laboratories, Hercules, CA, USA). 15 μg of protein from each sample was separated 
on SDS-PAGE acrylamide gels and once complete, transferred to a PVDF membrane. After blocking with 
5% powdered milk, membranes were incubated overnight at 4 °C with the primary antibody Total OXPHOS 
Antibody Cocktail (1:1000, mouse, Abcam, #ab110413; Total AMPK-α (1:1000, rabbit, Cell Signalling, #2603 S); 
Phospho-AMPK Thr172 (1:1000, rabbit, Cell Signalling, #2535 s); PGC-1α (1:1000, mouse Merck Millipore, 
#ST1202); PGC-1β (1:3000, rabbit, Abcam, #ab176328); utrophin (1:200, mouse, Developmental Studies 
Hybridoma Bank (MANCH03 (8A4)-c; deposited by Morris, G.E.)). After overnight incubation, the mem-
branes were washed, incubated with a peroxidase-conjugated secondary antibody (1:20,000, anti-mouse, #PI-
2000; 1:5000, anti-rabbit, #PI-1000; Vector Labs) at room temperature and washed again. Images were captured 
(Fusion FX imaging system, Vilber Lourmat, Germany) once the blots were developed with ECL Prime reagent 
(Amersham, Piscataway, NJ, USA). Densitometric analysis was performed using Fusion CAPT Advance software 
(Vilber Lourmat, Germany). Membranes were then stained for total protein with Coomassie Blue40. The signal for 
the band of the protein of interest was then normalized to the signal for total protein in each lane.
Citrate synthase (CS) activity. CS activity was measured as a marker of mitochondrial density and/or 
anaplerosis41. Homogenised FDB fibres were added to the reagent cocktail (100 mM Tris Buffer, 1 mM DTNB, 
3 mM Acetyl CoA) and to initiate the reaction, oxaloacetate (10 mM) was added just prior to measuring CS activ-
ity spectrophotometrically (412 nm, 25 °C, 5 mins). CS activity was calculated using the extinction coefficient of 
13.642.
Metabolite quantification. ATP, phosphocreatine (PCr), creatine (Cr), lactate and glycogen metabolites 
were assessed in the left TA. At least 20 mg of frozen sample was weighed and freeze-dried at −40 °C (Edwards 
Modulo, Edwards High Vacuum, Britain, England) for a minimum of 48 hours. For ATP, PCr, Cr and lactate 
metabolite extraction, 2 mg of powdered sample was used while 1 mg of powdered was utilised for glycogen 
metabolite extraction. Metabolite analysis was performed in 96 well plates using a method adapted from Lowry 
and Passonneau43 as described by us previously44.
Statistics. Data are presented as mean ± standard error of the mean. A two-way ANOVA was utilised to 
detect genotype and treatment differences. When a main effect or an interaction was detected, unpaired T-tests 
were used to determine differences between individual groups using SPSS (version 21). An α value of 0.05 was 
considered significant.
Results
Effect of ASA on body weight, food and water consumption and muscle and organ 
weights. Throughout the 8-week treatment period, weight gain (% of pre-treatment body weight) was com-
parable between CON and mdx strains both with and without ASA treatment (Fig. S1A). However, post-treat-
ment body weights were different, with mdx mice being heavier compared to CON mice (p < 0.01, Table 1). 
ASA reduced the post-treatment body weight of mdx (p < 0.05, Table 1) but not CON mice, and this effect was 
independent of food and water consumption which was comparable between strain and treatment protocols 
(Fig. S1B,C). Hind limb muscle weights (EDL, gastrocnemius, quadriceps, SOL and TA) relative to body weight 
were heavier in mdx compared to CON mice (p < 0.01–0.0001; Table 1), except for mdx plantaris weights, which 
were comparable to CON. ASA had no effect on muscle weights in either strain, except for an anomaly reduction 
in the right CON TA which was not evident in the left CON TA (p < 0.05).
Since DMD boys die from cardiorespiratory insufficiency, we also measured heart, diaphragm and lung 
weights to determine any effects of genotype or ASA treatment on the cardiorespiratory system. While the dia-
phragm weight relative to body weight was higher in mdx compared to CON mice (p < 0.01) as per the hind limb 
skeletal muscles, the heart weight relative to body mass was reduced in mdx compared to CON mice (p < 0.01) 
and there was a strong trend for a similar genotype-dependent reduction in lung weight (p = 0.060). ASA reduced 
the lung weight in CON (p < 0.05) but not mdx mice and had no effect on the mass of the diaphragm or any other 
organ assessed.
ASA ameliorates histopathology. ASA reduces pseudohypertrophy and damage in mdx TA. The mean 
fibre CSA was 17% greater in untreated mdx compared to CON TA (p < 0.05, Fig. 1C), which was associated 
with a shift in fibre size distribution to the right due to there being a higher frequency of fibres with a larger 
CSA (6000–13499 μm2, p < 0.0001, Fig. 1A). ASA treatment reduced the mean fibre size in both CON and mdx 
TA by 7% and 21%, respectively (p < 0.05, Fig. 1C). In particular, a decrease in the number of fibres with a CSA 
between 6000 and 13499 μm2 was observed in mdx ASA-treated TA (p < 0.05, Fig. 1A), which shifted the fibre 
size distribution to the left (Fig. 1A). As expected, the proportional area of damage was significantly higher in 
mdx compared to CON TA (p < 0.001; Fig. 1D). While the damaged area represented only ~2% of the total CSA 
(which is consistent with the stabilisation phase characteristic of 12w old mdx mice), ASA remarkably reduced 
the damaged area by 46% in mdx TA (p < 0.05, Fig. 1D). In ASA-treated mdx TA, the reduction in damaged area 
corresponded with a reduction (of 29%) in centronucleated fibres (an indicator of muscle regeneration) compared 
to untreated mdx TA (p < 0.01, Fig. 1E).
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ASA reduces lipid content of mdx TA. Previously it has been demonstrated that ASA reduces lipid production in 
DMD muscle explants45. As such, we assessed the effect of ASA on the lipid content of dystrophic muscle. Neutral 
lipids were quantified in whole cross-sections to give the overall ORO positive area. In mdx TA, the ORO positive 
area was 34% greater compared to CON TA (p < 0.001, Fig. 2A). ASA significantly reduced the ORO positive area 
by ~10% in mdx TA (p < 0.05).
ASA reduces the collagen content of mdx TA. Next, we assessed the effect of ASA on the connective tissue 
content of dystrophic muscle, since connective tissue accumulation and fibrosis is a feature of disease pro-
gression. In untreated mdx TA, connective/fibrotic tissue abundance was 15% greater compared to CON TA 
(p < 0.001, Fig. 2C). Remarkably, ASA normalised the connective/fibrotic tissue content in mdx TA to CON levels 
(p < 0.0001).
ASA reduces Ca2+ content of mdx TA. Since Ca2+ dysregulation is a well-documented consequence of 
dystrophin-deficiency and is a driver of the pathological muscle degeneration in DMD, we investigated whether 
ASA could positively modulate this important pathological feature. Intramuscular Ca2+ content, as assessed by 
the staining intensity of Alizarin Red, was 62% higher in untreated mdx compared to CON TA (p < 0.0001, 
Fig. 2E). Although, ASA had no effect on the Ca2+ content of CON TA (p > 0.05, Fig. 2E), ASA treatment signifi-
cantly reduced the Ca2+ content of mdx TA by 15% (p < 0.001).
ASA increases SDH in mdx TA. SDH, a mitochondrial enzyme shared by the TCA cycle and the electron trans-
port chain (ETC), is a marker of oxidative fibre type with deep purple fibres being characteristic of Type I fibres 
and lighter purple fibres being indicative of Type IIa fibres. Assessing the whole TA cross-sectional area for SDH 
staining indicates the total mitochondrial content of all fibre types. While there was no difference in SDH positive 
area between untreated CON and mdx TA (Fig. 2G), ASA treatment did increase the SDH positive area of both 
CON and mdx TA by 25% and 46%, respectively (p < 0.0001, Fig. 2G). This suggests a capacity to regulate mito-
chondrial content/density.
ASA has no effect on muscle contractile properties. A distinguishing feature of DMD progression 
is the replacement of functional skeletal muscle with non-functional fatty and connective tissue which results 
in reduced force production and myofibril pseudohypertrophy. Thus, we assessed contractile properties in the 
fast-twitch EDL and slow-twitch soleus muscle. There was no significant difference in Po between CON and mdx 
muscles or following ASA treatment (Fig. 1F). Despite an increase in CSA in both mdx EDL (p < 0.001, Fig. 1F) 
and mdx SOL compared to CON (p < 0.0001, Fig. 1F), the sPo of mdx EDL and SOL was still comparable (Fig. 1F), 
CON mdx
UNTREATED ASA UNTREATED ASA
Body weight (final, g) 30.2 ± 0.4 30.9 ± 0.4 32.4 ± 0.5^^ 31.3 ± 0.5^^ *
Diaphragm (mg/g bw) 2.76 ± 0.14 2.33 ± 0.21 3.37 ± 0.14^^ 3.53 ± 0.17
EDL (L, mg/g bw) 0.4 ± 0.02 0.42 ± 0.02 0.54 ± 0.02^^^^ 0.52 ± 0.03
EDL (R, mg/g bw) 0.38 ± 0.03 0.40 ± 0.01 0.53 ± 0.03^^^^ 0.50 ± 0.02
Gastrocnemius (L, mg/g bw) 4.84 ± 0.24 4.60 ± 0.13 5.66 ± 0.18^^ 5.59 ± 0.15
Gastrocnemius (R, mg/g bw/g bw) 5.07 ± 0.14 5.02 ± 0.16 5.97 ± 0.26^^ 5.67 ± 0.10
Heart (mg/ g bw) 4.76 ± 0.11 4.65 ± 0.09 4.40 ± 0.07^^ 4.28 ± 0.07
Liver (mg/g bw) 49.57 ± 1.36 47.85 ± 3.85 55.52 ± 1.06^ 55.12 ± 1.46
Lungs (mg/g bw) 6.74 ± 0.30 5.92 ± 0.24* 6.05 ± 0.19 5.68 ± 0.20
Plantaris (L, mg/g bw) 0.63 ± 0.04 0.65 ± 0.04 0.69 ± 0.03 0.70 ± 0.04
Plantaris (R, mg/g bw) 0.68 ± 0.08 0.62 ± 0.04 0.71 ± 0.02 0.70 ± 0.03
Quadriceps (L, mg/g bw) 6.5 ± 0.36 6.44 ± 0.22 8.97 ± 0.26^^^^ 8.95 ± 0.24
Quadriceps (R, mg/g bw) 6.24 0.34 5.92 0.27 8.16 0.21^^^^ 8.40 0.29
Soleus (L, mg/g bw) 0.37 ± 0.02 0.38 ± 0.02 0.48 ± 0.02^^^^ 0.50 ± 0.02
Soleus (R, mg/g bw) 0.35 ± 0.02 0.37 ± 0.02 0.44 ± 0.02^^^ 0.47 ± 0.03
Spleen (mg/g bw) 3.9 ± 0.1 4.0 ± 0.1 3.9 ± 0.2 3.8 ± 0.1
TA (L, mg/g bw) 1.6 ± 0.10 1.61 ± 0.08 2.30 ± 0.08^^^^ 2.23 ± 0.06
TA (R, mg/g bw) 1.87 ± 0.11 1.60 ± 0.05* 2.24 ± 0.05^^^ 2.23 ± 0.06
Table 1. Post treatment body weights and muscle and organ weights relative to the body weight of untreated 
and ASA-treated mice. Final body weights were significantly higher in mdx compared to CON mice (p < 0.01) 
with ASA reducing the body weight of mdx mice (p < 0.05). Relative to body weight, the weights of all skeletal 
muscles and organs were significantly higher in mdx compared to CON mice (p < 0.05), with the exception of 
the lungs, spleen and left and right plantaris which were comparable between genotypes (p > 0.05). ASA had 
no effect on the weight (mg/g bw) of any mdx tissues, but it did reduce the lung and right TA weight (mg/ g bw) 
in CON mice (p < 0.05). ^p < 0.05, ^^p < 0.01, ^^^p < 0.005, ^^^^p < 0.001 mdx significantly different from 
CON mice; *p < 0.05 ASA-treated significantly different from untreated n = 7–14 CON, n = 11–16 CON ASA, 
n = 10–16 mdx, n = 11–16 mdx ASA.95.
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Figure 1. ASA attenuates damage and pseudohypertrophy of mdx tibialis anterior (TA) but has no effect on 
contractile properties of the extensor digitorum longus (EDL) or soleus (SOL). The frequency histogram of 
CON (A), CON ASA (AI), mdx (AII) and mdx ASA (AIII) shows the shift in histogram shape. The red dotted line 
indicates the mean fibre size of CON TA fibres. Mean fibre size was larger in mdx compared to CON TA (p < 0.05, 
(B)) with ASA decreasing mean fibre size in both CON and mdx fibres (p < 0.05). Representative images of mdx 
(CII) and mdx ASA (CIII) TA cross sections indicate damaged areas (black arrows) and centronucleated fibres 
(white arrows) which are not evident in CON (C) and CON ASA (CI) TA. Damaged area (D) and percentage 
of centronucleated fibres (E) was significantly higher in mdx TA compared to CON (p < 0.001 and p < 0.0001 
respectively) with ASA decreasing damage and regeneration in mdx TA (p < 0.05 and p < 0.01, respectively). No 
significant differences in absolute or specific force (F) were observed in the EDL or SOL of any group. The muscle 
cross sectional area (CSA) was larger in mdx EDL (p < 0.001) and SOL (p < 0.0001) compared to CON. ASA 
increased the CSA of both CON and mdx EDL (p < 0.05). For histology: n = 9 CON, n = 9 CON ASA, n = 10 mdx, 
n = 11 mdx ASA. For EDL contractile: n = 11 CON, n = 15 CON ASA, n = 5–6 mdx, n = 13–15 mdx ASA. For SOL 
contractile: n = 9–12 CON, n = 12 CON ASA, n = 6 mdx, n = 13–14 mdx ASA. Scale bar = 50 μm.
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Figure 2. Assessment of lipid accumulation (ORO), connective tissues (Gomori), Ca2+ content (Alizarin 
Red) and succinate dehydrogenase (SDH) content in TA from untreated and ASA-treated CON and mdx 
mice. Oil Red O (ORO) positive area of mdx TA was significantly higher compared to CON (p < 0.001, A) 
with ASA reducing ORO positive area of mdx TA compared to mdx UNSUPP (p < 0.05). Connective tissue 
was also significantly higher in mdx TA compared to CON (p < 0.001, C) with ASA reducing the connective 
tissue content of mdx TA (p < 0.0001). Ca2+ content was significantly higher in mdx TA compared to CON 
(p < 0.0001, E) with ASA reducing Ca2+ content in mdx TA (p < 0.001). The SDH positive area was comparable 
between CON and mdx TA (p > 0.05, G) with ASA increasing the SDH positive area in both CON ASA and 
mdx ASA TA (p < 0.0001). n = 8–12 CON, n = 10–12 CON ASA, n = 9–12 mdx, n = 10–12 mdx ASA. Scale 
bar = 50 μm.
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albeit mdx EDL were ~20% lower than CON. These data are somewhat consistent with a higher non-functional 
tissue content of fast-twitch muscles as demonstrated histologically in the TA. In both CON and mdx EDL, ASA 
increased the CSA compared to CON (Fig. 1F), however this effect was not observed in SOL (Fig. 1F) and had 
no effect on sPo.
Effects of ASA treatment on mitochondrial and metabolic parameters. Respirometry. 
Considering the significant improvements in energy and stamina reported by patients in the ASA clinical trial20, 
and the capacity of purine nucleotide cycling to both generate fumarate for anaplerosis and potentiate ade-
nine nucleotide salvage, we investigated whether the improvements in muscle histopathology might be due to 
improved mitochondrial function. As we could not reliably quantify protein content of the wells to internally 
correct respiration values for mitochondrial density due to very low protein concentrations, here we present res-
piration parameters that are internally corrected for the basal respiration.
Using a mitochondrial stress test, we first determined the metabolic potential (corrected for basal respira-
tion rate39) of the OCR and ECAR, which demonstrates the capacity of the metabolic pathways to ramp up in 
response to FCCP-induced mitochondrial uncoupling and depletion of the ∆Ψ for mitochondrial oxidative and 
cytosolic anaerobic metabolism, respectively. The oxidative metabolic potential, which assesses the capacity to 
potentiate oxidative metabolism during metabolic stress, was reduced by ~20% in mdx compared to CON FDB 
fibres (p < 0.01, Fig. 3A). In contrast, the glycolytic metabolic potential, which assesses the capacity to potentiate 
glycolysis during metabolic stress, was ~110% higher in mdx compared to CON FDB fibres (p < 0.01, Fig. 3B) 
demonstrating a shift toward a more anaerobic phenotype. The mitochondrial coupling efficiency, which indi-
cates the extent to which ATP production at Complex V (CV) is matched to oxygen consumption at Complex 
IV (CIV), was comparable in CON and mdx FDB fibres (Fig. 3C). Contrary to our hypothesis that ASA would 
induce anaplerosis, there was no effect of treatment on either the oxidative or anaerobic metabolic potential, or 
the coupling efficiency, in CON or mdx FDB fibres. Of note, there was no ASA exogenously introduced into the 
assay, thus, the potentially short-lived effects of ASA may have been lost once the muscle was removed from the 
blood supply (and therefore the ASA supply) and incubated for 24 hours. To test this possibility, we next meas-
ured CS activity in FDB fibres that were snap frozen immediately after isolation, as an indicator of mitochondrial 
functional capacity (particularly that of Complex II (CII))46,47. While there was no difference in the CS activity 
of CON and mdx FDB fibres (Fig. 3D), ASA treatment did increase CS activity by 24% in CON fibres (p < 0.05) 
demonstrating anaplerotic capacity. Interestingly, ASA treatment had no effect on mdx fibres (p > 0.05), support-
ing our previous findings that mdx mitochondrial do not respond normally to metabolic stimulants17.
Mitochondrial Viability and Superoxide (O2−) Production. Since ASA was shown to stimulate CS activity only in 
CON muscle, we have investigated other potential effects of ASA at the mitochondrial level. First, we quantified 
the total mitochondrial pool (using MitoTracker green) and demonstrated that, while mitochondrial content is 
comparable between untreated CON and mdx fibres (Fig. 3E), ASA treatment was able to increase mitochondrial 
content in both strains by 55% and 208%, respectively (p < 0.01). Next, we assessed the viability of the mito-
chondrial pool by the ratio of live mitochondria (MitoTracker red) to the total mitochondrial pool (MitoTracker 
green). Mitochondrial pool viability was comparable in untreated CON and mdx FDB fibres (Fig. 3F). While ASA 
had no effect on mitochondrial pool viability in CON fibres, it did increase the viability of the mitochondrial pool 
in mdx fibres by 17% (p < 0.05, Fig. 3F).
Next, we assessed the effect of ASA on mitochondrial O2− production to determine whether stimulating mito-
chondrial capacity merely resulted in enhanced reactive oxygen species (ROS) production, which could explain 
the lack of respiratory modulation. While there were no differences in the mitochondrial O2− content of untreated 
CON and mdx fibres (Fig. 3G), ASA treatment increased O2− production by 28% (p < 0.05) in CON fibres which 
was consistent with the stimulation of CS activity (24% increase). Although there was no anaplerotic effect of ASA 
treatment on CS activity, ASA decreased the O2− content of mdx fibres by 26% (p < 0.05). Since ASA had no effect 
on mitochondrial coupling, these data suggest that in mdx muscle, ASA may induce an antioxidant response to 
improve the redox status of FDB fibres.
To interrogate the idea that ASA might modulate muscle redox status, we next assessed the relative 
time-course of changes in mitochondrial O2− content in immortalised myoblasts derived from healthy CON and 
dystrophin-deficient DMD patients. Cells were treated with ASA for 24 hours, 3 days or 7 days and mitochondrial 
O2− content relative to mitochondrial density was assessed using MitoSOX and MitoTracker Green dyes, respec-
tively36. As described in Supplementary Fig. 3, 24-hour ASA treatment significantly increased mitochondrial 
O2− content in DMD but not CON myoblasts. However, following 3 and 7 days treatment, ASA treatment signif-
icantly reduced the mitochondria O2− content. These data support the notion of an ASA-dependent induction of 
the myofibre redox state.
Electron Transport Chain (ETC) Complex Expression. The stimulation of mitochondrial biogenesis to enhance 
mitochondrial content without the concomitant upregulation of mitochondrial respiratory chain proteins to 
increase oxidative capacity is futile, and is characteristic of a fission phenotype in which ROS production replaces 
ATP production48. As such, we next assessed ETC complex expression to elucidate whether the capacity of ASA 
to enhance mitochondrial content translated to the modulation of respiratory chain density. As we did not have 
sufficient FDB fibres following respiratory analysis, we utilised the quadriceps for Western blot analysis due to a 
similar fibre type composition49–52. In all subunits quantified from CI to CV, no difference was detected between 
CON and mdx quadriceps (p > 0.05, Fig. 4). ASA had no effect on the expression of any of the mitochondrial 
complex subunits assessed in either strain which, together with an incapacity to modulate the oxidative potential, 
suggests that ASA induces fission (i.e. more, but smaller and less functional mitochondria) rather than biogenesis 
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Figure 3. Mitochondrial function, viability, density and superoxide (O2−) production in isolated FDB fibres 
from untreated and ASA-treated CON and mdx mice. The oxidative metabolic potential was significantly less in 
mdx compared to CON FDB fibres (p < 0.01, A) while the glycolytic metabolic potential was higher (p < 0.01, 
B). ASA had no effect in either strain (p > 0.05). No differences in coupling efficiency was observed between 
CON and mdx FDB fibres (p > 0.05, C). In CON fibres, ASA increased citrate synthase (CS) activity (p < 0.05, 
D) with ASA having no effect in mdx ASA fibres (p > 0.05). In both CON ASA and mdx ASA fibres, ASA 
increased the total mitochondrial pool compared to untreated fibres (p > 0.01, E). The mitochondrial viability 
was comparable in CON, CON ASA and mdx fibres (p > 0.05, F). ASA increased mitochondrial viability in mdx 
ASA compared to untreated mdx fibres (p > 0.05). In CON fibres, ASA increased O2− production (p < 0.05, G) 
while in mdx fibres, ASA decreased O2− production (p > 0.05). n = 9–11 for mitochondrial function and n = 3 
for mitochondrial viability, pool and O2− production CON, n = 9–10 for mitochondrial function and n = 6–7 
for mitochondrial viability, pool and O2− production CON ASA, n = 10–14 for mitochondrial function and 
n = 6–10 for mitochondrial viability, pool and O2− production mdx, n = 10–15 for mitochondrial function and 
n = 6–8 for mitochondrial viability, pool and O2− production mdx ASA.
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(i.e. more, fully-functional mitochondria that increase the overall respiratory capacity) in both strains, but more 
so in mdx muscles.
Metabolites. To determine whether ASA could influence the overall metabolic signature of the skeletal muscle, 
we next evaluated the metabolite content of TA. In contrast to data described previously, the Cr, PCr, TCr, ATP 
and lactate content was comparable between untreated CON and mdx TA (Fig. 5A–E). While ASA had no effect 
on Cr content in mdx TA (Fig. 5A), ASA reduced the Cr content by 21% (p < 0.05) but increased intramuscular 
Figure 4. Mitochondrial respiratory chain complex proteins of the quadriceps from untreated and ASA-
treated CON and mdx mice. No significant difference was detected between CON and mdx quadriceps in any 
subunit of the ETC complexes (p > 0.05, A–E). There was also no effect of ASA treatment (p > 0.05, A–E). 
Representative western blots of proteins from each of the five mitochondrial respiratory complexes (F). n = 8 
per group.
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PCr content by 61%, in CON TA (p < 0.01, Fig. 5B), demonstrating enhanced high energy phosphate stores. The 
PCr content of mdx TA was also increased by 33% by ASA treatment (p < 0.01, Fig. 5B). As such, the TCr content 
was positively modulated by ASA treatment with a 17% and 13% increase in CON and mdx TA, respectively 
(p < 0.05, Fig. 5C). While ASA had no effect on the ATP content of mdx TA (Fig. 5D), there was a strong trend 
for ASA to increase ATP content in CON samples (p = 0.05). While, glycogen content was ~50% higher in mdx 
compared to CON TA (p < 0.01, Fig. 5F), consistent with an anaerobic phenotype, there was no effect of ASA on 
this metabolite in either strain.
Metabolic stress signalling. During metabolic stress, when ATP cannot be resynthesised sufficiently to match 
metabolic demand, adenine nucleotides are rapidly degraded (ATP → ADP → AMP)53. Rising AMP levels acti-
vate AMP-activated protein kinase (AMPK) to modulate various responses to support ATP production, such as 
Figure 5. Intramuscular Cr, PCr, TCr, ATP, lactate and glycogen content of untreated and ASA-treated CON 
and mdx mice. No significant difference in Cr content was detected between CON and mdx TA (p > 0.05, A) 
with ASA increasing Cr content in CON ASA TA only (p < 0.05). While PCr content was comparable between 
CON and mdx TA (p > 0.05, B), ASA increased PCr content in both CON ASA and mdx ASA TA (p < 0.01). 
Similarly, although no genotypic differences were detected (p > 0.05, C), ASA increased TCr content in both 
CON ASA and mdx ASA TA (p < 0.05). ATP content was comparable between CON and mdx TA (p < 0.05, 
D) and there was a trend for ASA to increase ATP content in CON ASA only (p = 0.056). Lactate content was 
also comparable between CON and mdx TA (p > 0.05, E) and ASA had no effect. Overall, glycogen content was 
higher in mdx compared to CON (p < 0.01, F) TA and ASA had no effect in either genotype. Full-length blots 
are presented in Supplementary in Fig. 2. n = 6–12 CON, n = 8–14 CON ASA, n = 8–15 mdx, n = 8–15 mdx 
ASA.
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mitochondrial biogenesis, lipid metabolism and autophagy (as reviewed in54); thus preventing further breakdown 
of AMP to IMP. ASA supports the recovery/salvage of IMP to AMP, thus AMP-dependent metabolic adapta-
tions might be a mechanism through which ASA exerts its therapeutic efficacy in dystrophin-deficient muscle. 
Phosphorylated AMPK (P-AMPK Thr172), a molecular marker of AMPK activation, was comparable between 
untreated CON and mdx quadriceps in our samples (Fig. 6A). Interestingly, and consistent with the ASA-induced 
increase in ATP content, ASA reduced P-AMPK in CON muscle only (by 47%; p < 0.05) but had no effect in 
mdx quadriceps. Total AMPK protein was also comparable between the strains, and ASA had no effect on this 
measure (Fig. 6B). While the ratio of P-AMPK to total AMPK was comparable between untreated CON and mdx 
Figure 6. Metabolic signalling of untreated and ASA-treated CON and mdx mice. Phosphorylated AMPK 
(P-AMPK) was not different between CON and mdx quadriceps (p > 0.05, A) with ASA decreasing P-AMPK in 
CON ASA only (p < 0.05). There was no difference in Total AMPK (p > 0.05, B) detected between either strain 
or treatment regimen. Similarly, there was no difference in P-/Total AMPK ratio observed between CON and 
mdx TA (p > 0.05, C), however, while ASA had no effect on P-/Total AMPK ratio in mdx ASA quadriceps, there 
was a trend for ASA to decrease the ratio in CON ASA quadriceps (p = 0.058). PGC-1α and –β protein content 
was higher in mdx quadriceps compared to CON (p < 0.05, D and E respectively) with ASA having no effect 
(p < 0.05). Utrophin was elevated in mdx compared to CON TA (p < 0.05, F) and again, ASA had no effect in 
either strain. n = 7–8 CON, n = 6–8 CON ASA, n = 6–8 mdx, n = 6–7 mdx ASA.
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quadriceps (Fig. 6C) and there was no effect of ASA treatment on mdx quadriceps, there was a strong trend for 
ASA to reduce this ratio in CON quadriceps (p = 0.058). Expression of the downstream regulators of mitochon-
drial biogenesis, PGC-1α and -1β, were elevated in mdx quadriceps by 34% and 149%, respectively, compared 
to CON quadriceps (p < 0.05, Fig. 6D,E respectively) with no effect of ASA. ASA thus appears to enhance meta-
bolic stress response signalling (presumably by increasing AMP concentration) sufficient to increase ATP content 
(and presumably the ATP/AMP ratio) and decrease AMPK phosphorylation in CON muscle, but not in mdx 
muscle. This infers that the protective effect of ASA treatment on mdx histopathology is independent of AMPK 
modulation.
ASA does not modulate utrophin expression. To explore the potential that ASA might act as a genetic modifier of 
DMD due to the beneficial effects observed in histopathology, we assessed utrophin expression in TA. Utrophin 
expression is notably upregulated in the mdx mouse in the absence of dystrophin, resulting in a milder phenotype 
compared to humans55, and is induced by AMPK56. As expected, utrophin protein was ~4-fold higher in mdx TA 
(p < 0.05, Fig. 6E); however, ASA had no effect on utrophin expression in neither CON nor mdx TA.
Discussion
While dystrophin-deficiency and sarcolemmal disturbance underpins DMD pathology, several lines of evidence 
highlight that metabolic insufficiency is a key aetiological modulator of disease progression (reviewed in14 and19). 
Considering the pivotal role that the mitochondria play in determining cell life and death, and the strong clini-
cal data showing efficacy of the mitochondria-targeted CoQ10 analogue, idebenone, for attenuating respiratory 
decline in human DMD patients18,57, we investigated the potential of metabolic purine nucleotide therapy to 
ameliorate murine DMD. In particular, we examined the efficacy of the purine nucleotide ASA – which has 
anecdotally induced improvements in clinical indices of DMD progression20 – to pre-clinically re-evaluate it as a 
potential candidate for the treatment of DMD.
A striking finding in our study was that ASA therapy ameliorated key histopathological features of 
dystrophin-deficient muscle. Importantly, ASA reduced pseudohypertrophy, damage and, therefore, regenerative 
features (i.e. centronucleated fibres), fibrotic and lipid tissue infiltration, and Ca2+ content in mdx muscle. These 
histopathological features are most prominent as DMD advances58–62 and potentiate the deterioration of the func-
tional capacity of skeletal muscles63,64. While we observed no improvements in tetanic force production following 
ASA treatment or in mdx compared to CON muscles, this finding is perhaps more reflective of limitations in the 
use of the mdx model rather than a lack of translatable functional improvement. Older (~100 day old) mdx mice 
have been previously shown to produce comparable forces to wild-type controls65 and reflects a regenerative 
capacity/stabilisation of the murine disease phenotype that is not observed in DMD patients. In this instance, 
an increase in fibre number and size functionally compensates for histopathological deterioration of the muscle. 
The reduced damage, and lipid and connective tissue infiltration following ASA treatment in our study highlights 
improvements in muscle integrity and quality that likely explain the maintenance of muscle strength and function 
observed in DMD and BMD patients treated with ASA previously20. Indeed, the same group has demonstrated 
excessive lipid production in explants of dystrophic muscle from DMD patients compared to healthy muscle 
cells45, which was also attenuated in the presence of ASA45,66. These data highlights translatable benefits of ASA 
for the treatment of DMD histopathology across murine and human species which apparently lead to func-
tional improvements in human patients, whilst not necessarily in mdx mice. Notably, the ASA-dependent histo-
pathological improvements observed in our study are independent of upregulated utrophin expression, the most 
well-established genetic modifier of murine DMD. While we cannot rule out the possibility of other genetic mod-
ifiers being influenced by ASA treatment, our data appears to consolidate a metabolic mode of action for ASA.
Metabolic dysfunction is a well-documented characteristic of dystrophic muscle, which is a contributing fac-
tor to disease progression (reviewed in14). We have demonstrated a reduced capacity of mdx muscle to utilise 
oxidative metabolism during metabolic stress (i.e. following FCCP-induced uncoupling in our experiments) 
albeit comparable ATP content in CON and mdx TA. Reduced ATP content has been widely reported in human 
DMD muscle (reviewed in14), but is difficult to accurately quantify given the transient nature of the molecule. 
A full metabolomics analysis would be required to ascertain the impact of reduced oxidative capacity on the 
metabolic systems, and the lack of one in this study is a limitation. Interestingly, our mitochondrial observa-
tions occurred despite increased PGC-1α (which has been previously observed56) and PGC-1β protein expres-
sion (reported for the first time here, albeit in quadriceps muscle). As there was no downstream increase in 
mitochondrial respiration, nor a difference in CS activity, SDH staining or mitochondrial density (assessed by 
MitoTracker Green) in untreated mdx compared to CON muscle, our data highlight that, despite an increased 
signal, dystrophin-deficient muscles do not adaptively expand the mitochondrial pool. While we did not observe 
differences in the expression of subunits of the ETC complexes between CON and mdx quadriceps (which would 
indicate a potential reason for the inability to increase ATP production), it is plausible that expression of other 
subunits of the ETC complexes are depressed or their activity is impaired. We have previously demonstrated that 
CI-mediated ATP production is severely impaired in mdx mitochondria irrespective of substrate supply, but that 
this can be attenuated with CI inhibition and stimulation of CII respiration17. When considered in context of 
our current data showing comparable mitochondrial content and expression of ETC subunits in mdx and CON 
muscle, these findings collectively suggest that functional impairments, possibly at CI, may be responsible for the 
impaired mitochondrial respiration. That being said, recent data has highlighted that immunoblotting may not be 
sensitive enough to detect small but physiologically relevant changes in protein expression at the mitochondrial 
level67. As such, structural impairments might also be accountable for our functional data, yet undetectable via 
Western blot.
Of note, mdx fibres appear to compensate for their reduced oxidative potential by increasing both their gly-
cogen stores and their capacity for anaerobic glycolysis during metabolic stress. However, to what extent such 
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compensation exists in vivo is unknown. While we have previously demonstrated that basal and exercise-induced 
glucose uptake are unaffected in mdx muscles35, enzymatic dysfunctions have been reported in the glycolytic path-
way68–71 and could, therefore, limit the potential for anaerobic metabolism to buffer prolonged metabolic stress. 
Similarly, phosphorylase (the enzyme that breaks down glycogen) activity is reduced in dystrophin-deficient skel-
etal muscle58,68–78, thus it is unlikely that the compensatory upregulation of glycolytic flux could sustain metabo-
lism in vivo in mdx mice. Certainly, when provided an opportunity for voluntary exercise, mdx mice are unable to 
run at the same speeds as their CON counterparts15.
We hypothesised that ASA could improve the metabolic capacity of dystrophic muscles by enhancing PNC 
function and thus purine nucleotide salvage, but particularly, by increasing fumarate production and anaplerosis 
of the mitochondrial TCA cycle14,19. Despite having previously demonstrated an impaired mitochondrial ATP 
production rate in isolated mdx mitochondrial bathed in optimal TCA substrate cocktails17, we and others have 
shown a partial attenuation of this mitochondrial dysfunction by stimulating CII with succinate25–28,79–81. Thus, 
we predicted in this study that promoting anaplerosis could, at the very least, augment SDH activity and the 
respiratory capacity of CII-mediated OXPHOS. However, our data demonstrate that ASA therapy is unable to 
modulate any of the mitochondrial parameters measured in FDB fibres in either CON or mdx mitochondria and 
is despite improving the viability and the density of the mitochondrial pool (as detected by MitoTracker dyes in 
dissociated FDB fibres). Our data was unexpected as the clinical trial of ASA in DMD and BMD patients anecdo-
tally reported increases in stamina and energy levels while functional measurements were maintained20, which 
suggests that ASA can improve muscle fatigue properties. We did observe, however, that ASA induced changes 
in PCr content and the TCr pool suggesting manipulation of the Cr/PCr system to improve the energy buffering 
capacity and maintenance of ATP levels. Since TCr is the only metabolite measurement that is not influenced by 
the time-course of the experimental procedures (i.e. because it accounts for both high phosphate and degraded 
phosphate carrier, and, therefore, variations in the time taken to extract and snap freeze muscles) these are impor-
tant data metabolically as it appears that some level of metabolic modulation is occurring in mdx muscle. The lack 
of effect of ASA at the mitochondrial level may be due to a few reasons. Firstly, as there is very limited literature 
regarding the human consumption of ASA, let alone as a metabolic therapy to treat neuromuscular disorders, it 
is unknown how long lasting the effects of ASA are. The improvements observed in the DMD and BMD patients 
in Bonsett and Rudman’s Phase I clinical trial were measured during the treatment period, which constituted 
infusion of ASA into the bloodstream via a miniature insulin pump20. In contrast, our mitochondrial measure-
ments were made in FDB fibres removed from the in vivo (and ASA) environment some 24 hours earlier, thus 
the acute effects of ASA on the muscle – such as fumarate production and mitochondrial anaplerosis – may have 
been significantly dampened or completely lost due to the wash out of ASA. There is the potential that this purine 
metabolite has a short half-life and, therefore, any downstream anaplerotic effects on the TCA cycle and mito-
chondrial respiration may not be observed within our experimental timeframe (i.e. 24 hours post-tissue harvest). 
The fact that CS activity was assessed in snap frozen muscles and was significantly enhanced by ASA treatment 
in CON mice, certainly suggests that ASA therapy has an anaplerotic effect at the mitochondrial level. However, 
this effect was not observed in mdx muscles, highlighting the possibility of several genotype differences: (1) that 
ASA-induced anaplerosis cannot occur in dysfunctional mitochondria, perhaps due to the CI-defect purported 
by us previously17, or due to the malate dehydrogenase deficiency that has been reported by others82, resulting in 
substrate accumulation and inhibition of ATP synthesis; (2) that the conversion and transport of ASA-generated 
fumarate/malate via the malate-aspartate shuttle is defective; or (3) that ASA-generated fumarate is being seques-
tered away from the mitochondria into cytosolic reactions83.
The lack of obvious metabolic modulation by ASA appears to be specifically related to the mdx geno/
pheno-type, since in CON muscles, ASA treatment did modulate some metabolic parameters. In particular, ASA 
increased ATP, reduced AMPK phosphorylation and apparently stimulated mitochondrial fission and anaplerosis 
as evidenced by increased MitoTracker green fluorescence without PCG-1α/β or ETC protein upregulation and 
increased CS activity, respectively. It has been postulated that a key role of mitochondrial fission is to prevent 
sustained mitochondrial elongation, which has been associated with the triggering of cellular senescence84,85 
suggesting a cytoprotective role for ASA. Moreover, ASA altered the Cr/PCr system in CON mice which led to 
enhancement of the high energy phosphate pool (PCr and ATP). These data highlight beneficial effects, yet poten-
tially differential mechanisms of action of ASA in CON and mdx mice. For CON mice, ASA-generated fumarate 
may be sequestered into the mitochondria, but without a heightened metabolic demand, anaplerosis seems to 
enhance O2− as opposed to ATP production. This is presumably because: (1) ATP demand is being met; and (2) 
purine salvage is enhanced, thus alleviating the role of mitochondria in maintaining the bioenergetical status of 
the muscle. In contrast, ASA-generated fumarate may be directed into alternative reactions in mdx skeletal muscle 
to induce beneficial effects on dystropathology. While the mechanisms underlying the beneficial effects of ASA 
in mdx skeletal muscle remain unclear, ASA was shown to enhance mitochondrial viability and reduce O2− pro-
duction in mdx FDB muscles and in human DMD myoblasts after 3 and 7 days exposure. Oxidative stress is a 
well-documented feature of dystrophic muscle8, potentially due to the down-regulation of redox genes86. While 
we unexpectedly demonstrated comparable mitochondrial O2− production between CON and mdx FDB fibres, 
the mitochondrial O2− content of human DMD myoblasts was markedly higher than healthy controls at 24 hours 
and 7 days. FDB is a predominantly fast-twitch muscle and thus is not particularly dependent upon mitochondrial 
oxidative phosphorylation as a driver of ATP generation or likely a strong generator of ROS. Interestingly, ASA 
initially induced mitochondrial O2− production in DMD myoblasts only and presumably reflects the metabolic 
stimulation of defective mitochondrial in which anaplerosis feeds ROS rather than ATP production. Whether it 
is the initial enhancement of ROS production or a direct modulation of the antioxidant response by ASA, which 
leads to modulation of the antioxidant response remains unclear. Nevertheless, the reduction of mitochondrial 
O2− production via ASA is a positive finding in this study since radical production in dystrophin-deficient muscle 
is associated with enhanced muscle fibre damage and degeneration8,87. It has been previously demonstrated that 
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fumarate content and cytosolic fumarase activity affects the redox status of the cell88,89. Increased fumarate con-
tent promotes glutathione production88 while the activity of cytosolic fumarase drives the malic enzyme reaction 
which generates NADPH90, thereby promoting the antioxidant status of the cell. Modulating cellular antioxidant 
systems such as that regulated by the glutathione system may be the mechanism through which ASA improves 
antioxidant defence in dystrophic muscle and, thus, warrants further investigation.
As this study is the first to experimentally evaluate ASA in a murine model, we closely monitored body weight 
and food and water consumption throughout treatment. No difference in weekly weight gain or food and water 
consumption was observed throughout the treatment period, although ASA did reduce the post-treatment body 
weights of mdx mice. While this was not reflected in differences in muscle weights relative to body weight, we did 
observe a decrease in lipid content of ASA treated mdx TA’s as detected by histology. Our data is consistent with 
a previous study that demonstrated reduced lipid production by DMD muscle explant cultures following ASA 
treatment66. The stimulation of β-fat oxidation may account for the reduced lipid content observed in our study, 
since it is plausible that lipid accumulation in dystrophic skeletal muscle results from a combination of enhanced 
lipid production66 and reduced fatty acid oxidation91–94. Once more, further investigation is required to elucidate 
the effect of ASA on body composition (i.e. via DEXA and/or micro-CT) and whether the modulation of lipid 
production compared to utilisation is a potential therapeutic mechanism of action.
conclusion
In summary, we are the first to demonstrate a remarkable capacity for ASA to ameliorate the histopathological 
hallmarks of murine DMD. This includes a reduction in intramuscular Ca2+ content, muscle damage and lipid 
and fibrotic tissue infiltration. ASA had no modulatory effect on mdx mitochondrial respiration although there 
was evidence of mitochondrial anaplerosis observed in healthy CON muscle, consistent with an underlying mito-
chondrial dysfunction in mdx muscles. Despite this, ASA reduced mitochondrial O2− production, improved the 
density and viability of the mitochondrial pool and improved the overall metabolic signature of dystrophic mdx 
skeletal muscle. While we observed no functional (contractile force) improvements in mdx muscles following 
ASA treatment, we also saw no differences between CON and mdx muscles highlighting the limitations of the 
mdx mouse model at this age. Thus, future pre-clinical evaluation of ASA as a therapeutic candidate for DMD 
should utilise mdx mice undergoing active damage and associated loss of strength (i.e. at a young age (~28 days) 
or following exercise-induced damage). While the precise mechanism of action and a full characterisation of the 
antioxidant, cytoprotective and contractile function effects of ASA requires further elucidation, our data along-
side anecdotal clinical observations in DMD patients, warrants further investigation of ASA as a therapeutic 
candidate for the treatment of DMD.
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